Targeting T regulatory cells: Their role in colorectal carcinoma progression and current clinical trials. (April 2022)

• Record Type: Journal Article
• Authors: Bandaru, Sai Samyuktha; Boyilla, Rajendra; Merchant, Neha; Nagaraju, Ganji Purnachandra; El-Rayes, Bassel F.
• Is Part Of: Pharmacological research. Volume 178(2022)
• Publication Date: 2022-04
• Subjects: cAMP cyclic monophosphate -- CRC colorectal cancer -- CTLA-4 cytotoxic T lymphocyte antigen 4 -- FOXP3 forkhead box P3 -- FOLFOX folinic acid, fluorouracil, oxaliplatin -- GITR glucocorticoid induced TNFR-related protein -- IBD inflammatory bowel disease -- IDO indoleamine 2, 3-dioxygenase -- IHC immunohistochemistry -- iTreg induced regulatory T cell -- LFA-1 lymphocyte function associated antigen 1 -- MHC major histocompatibility complex -- nTreg naturally occurring regulatory T cell -- TAA tumor associated antigens -- Tconv conventional T cell -- TCR T cell receptor -- Treg regulatory T cell; T regulatory cells -- Tumor microenvironment -- Tmmune cells -- Progression -- Colorectal cancer; Pharmacology -- Periodicals; Pharmacology -- Periodicals; Research -- Periodicals; Médicaments -- Recherche -- Périodiques; Pharmacologie -- Périodiques; 615.105
• DOI: 10.1016/j.phrs.2022.106197
• Languages: English
• ISSNs: 1043-6618

Abstract

Abstract: Colorectal cancer (CRC) is classified as the third leading cancer globally and one of the major causes of morbidity and mortality around the world. The interaction of the immune system with the cancer cells plays a vital role in CRC progression. Regulatory T cells (Tregs) are a form of T cells, which regulate and suppress unwanted activation of the immune system and play a major role in preventing autoimmune diseases. Tregs exhibit a significant role in immune modulation during CRC progression through accumulation in the tumor microenvironment (TME) and suppression of immunity against tumor specific antigens promoting tumor progression. The role of Tregs in CRC progression and its interaction with other immune cells within CRC TME and current clinical trials were reviewed in this paper. Graphical Abstract: ga1 Highlights: Discusses the role of Tregs in immune modulation during CRC progression. Explores the role of Tregs in CRC tumor microenvironment. Highlights the mechanism of Tregs in CRC growth and metastasis. Identifies and discusses current clinical trials targeting Tregs in CRC therapy.